anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Promethazine HCl Injection USP, is a sterile, pyrogen-free solution for deep intramuscular or intravenous administration. Promethazine HCl (10H-Phenothiazine-10 ethanamine,N,N,α-trimethyl-, monohydrochloride, (±)-) is a racemic compound and has the following structural formula: 

C17H21ClN2S MW 320.88 

Each mL contains Promethazine HCl, either 25 mg or 50 mg with 0.1 mg edetate disodium, 0.04 mg calcium chloride, 0.5 mg sodium metabisulfite in water for injection. The pH range is 4.0 to 5.5; buffered with acetic acid-sodium acetate, and it is sealed under nitrogen.

Promethazine HCl Injection is a clear, colorless solution. The product is light sensitive. It should be inspected before use and discarded if either color or particulate is observed.
KEY POINTS: Participants with CKD had detectable cognitive deficits in fluid cognition, dexterity, and total cognition. Sex differences in cognition exist in people with CKD.
BACKGROUND: CKD is largely an age-related clinical disorder with accelerated cognitive and cardiovascular aging. Cognitive impairment is a well-documented occurrence in midlife and older adults with CKD and affects multiple domains. We examined cognition function and potential sex differences in cognition in adults with CKD.
METHODS: We included 105 individuals (49.5% women) with CKD stage 3b–4 (eGFR, 15–44 ml/min) from the Bicarbonate Administration in CKD Trial (NCT02915601). We measured cognitive function using the National Institutes of Health Toolbox Cognition Battery, which assesses cognitive and motor measures, such as executive function, attention, memory, and dexterity. All study measures were collected and analyzed at the study baseline.
RESULTS: The mean (SD) age and eGFR were 61±12 years and 34.9±9.8 ml/min per 1.73 m2. Overall, when compared with the National Institutes of Health Toolbox reference population, participants scored, on average, below the 50th percentile across all cognitive domain tests and the dexterity test. Total cognition scores were also below the 50th percentile. Participants with stage 4 CKD had significantly lower fluid cognition scores compared with those with CKD stage 3b (β-estimate −5.4 [95% confidence interval, −9.8 to −0.9]; P = 0.03). Female participants with CKD performed significantly better on the episodic memory tests and dexterity tests (dominant and nondominant pegboard tests) and had higher crystallized cognition scores, on average, compared with male participants.
CONCLUSIONS: Participants with CKD had detectable cognitive deficits in fluid cognition, dexterity, and total cognition. In addition, sex differences in cognitive measures were found among people with CKD.
The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
The invention relates to a bovine hemoglobin nano-capsule blood substitute and a preparation method thereof, in particular to a novel multi-layer polysaccharide structure-modified liposome-encapsulated hemoglobin nano-capsule blood substitute. The nano-capsule contains a liposome inner core with positive charges and an outer layer modified with chitosan/dextran sodium composite polysaccharide polyelectrolytes by the layer-by-layer self-assembly method. The hemoglobin content of the nano-capsule is high and the oxygen-carrying activity of the nano-capsule is similar to that of the natural red blood cell. The preparation method comprises seven steps and finally a nano-capsule coated with seven layers of polyelectrolytes is obtained: L-(ED-CH)3-DE (L refers to liposome, i.e. the inner liposome layer; DE refers to dextran; and CH refers to chitosan), and the final product is collected. The preparation method has a simple process, reduces the consumption of organic solvents, has a mild reaction process, and minimizes the effect on the biological property of hemoglobin.
The present invention provides a cosmetic composition containing an extract of Euonymus fortunei var. radicans. The present invention offers an excellent skin condition improvement effect when a user uses the extract of Euonymus fortunei var. radicans especially the extract of Euonymus fortunei var. radicans seeds as a cosmetic material. The extract of Euonymus fortunei var. radicans seeds is aged for 10-20 hours at room temperature for maximizing the skin condition improvement effect of the extract of Euonymus fortunei var. radicans. [Reference numerals] (AA) Manufacturing radicans seed extract; (BB) Aging at room temperatures; (CC) Mixing cosmetic composition added ingredients
AIM: In patients with end-stage kidney disease (ESKD), it is unclear whether an imbalance between myocardial oxygen supply and demand leads to myocardial injury (MI). This study clarifies the association between the balance of the rate pressure product (RPP), consisting of the systolic blood pressure multiplied by the pulse rate (PR), a marker for myocardial oxygen demand, and hemoglobin (Hb), a marker for oxygen supply, with MI.
METHODS: A total of 283 consecutive unselected patients for hemodialysis were enrolled in this retrospective, cross-sectional study, and were divided into four groups according to Hb levels (high or low) and RPP. Potential imbalances between myocardial oxygen supply and demand were defined as patients with simultaneous high RPP and low Hb levels. The odds ratio (OR) for MI, defined as cardiac troponin T (cTnT) of ≥ 0.15 ng/mL was investigated using logistic regression analysis between the four patient groups.
RESULTS: The mean age was 68.7 years, 71.3% were men, and 52.6% had diabetes. The mean Hb level was 9.0 g/dL, and 20.5% of patients were latently diagnosed with MI. The median RPP and cTnT level was 12,144 and 0.083 ng/mL, respectively. When exposed to simultaneous high RPP with low Hb, OR significantly increased compared with that of the well-balanced group (RPP <12,500 and Hb ≥ 9.0 g/dL; OR 3.63, p<0.05). Similar results were obtained in multivariate analysis after adjusting for confounding variables. These associations were enhanced or weakened when the Hb cut-off level became lower (Hb=8 g/dL) or higher (Hb=10 g/dL).
CONCLUSIONS: As the myocardial oxygen supply and demand balance in patients with ESKD is potentially associated with MI, appropriate management for blood pressure, PR, and anemia may prevent MI.
Background: A capsule's physical design (e.g. shape, size, and color) affects individuals' perception of drug efficacy; that is, how well a drug is likely to work. The goal of this study is to assess the effects tablet size may have on participant's performance on cognitive testing since research has found differences between preparation methods. Method: 120 participants will be randomly assigned to one of four groups: 1) 90 mg caffeine with a 1 mm diameter sucrose pillule; 2) no caffeine with the small sucrose pillule; 3) 90 mg caffeine with a 5 mm sucrose pillule; 4) no caffeine with the large sucrose pillule. Participants will consume the designated placebo tablet with water (caffeinated or non-caffeinated); then, participants will provide weekly caffeine intake and complete the neutral portion of Velten's Mood Induction Procedure until 30 minutes have passed to allow for caffeine activation. Participants will complete the Stroop test, Trial Making Tests A and B, and the Rey Auditory Verbal Learning Test. Previous literature, as far as the author knows, relied on evaluating drug efficacy based on appearance alone. This study aims to assess if tablet size, due to placebo effect, alters participants' performance on cognitive tests after consuming caffeine.
Participants attend 6 sessions of Survivorship ECHO educational intervention over 1 hour each, every 2 weeks for 12 weeks. Participants may optionally participate in a one-on-one interview to give feedback about the sessions over 30 minutes.
Depression is one of the most frequent neuropsychiatric symptoms in corticobasal degeneration (CBD), a rare, sporadic, and late-onset progressive neurodegenerative disorder of unknown etiology. It is clinically characterized by a levodopa-poorly responsible akinetic-rigid syndrome, apraxia, limb dystonia, cognitive, mood, behavioral, and language disorders. This 4-repeat (4R) tauopathy is morphologically featured by asymmetric frontoparietal atrophy, neuronal loss, and gliosis in cortex and subcortex including substantia nigra, ballooned/achromatic neurons with filamentous 4R tau aggregates in cortex and striatum, widespread thread-like structures, pathognomonic "astroglial plaques", "tufted astrocytes", and numerous "coiled bodies" (in astrocytes and oligodendroglia) in cerebral white matter. CBD is non-specific, as pathologically proven cases include several clinical phenotypes. Pubmed and Google Scholar were systematically analyzed until October 2023, with focus on the prevalence, clinical manifestation, neuroimaging data, and treatment options of depression in CBD. Its prevalence is about 30-40% which is more frequent than in most other atypical parkinsonian syndromes. Depression usually does not correlate with motor and other clinical parameters, suggesting different pathophysiological mechanisms. Asymmetric atrophy and hypometabolism of frontoparietal cortical areas are associated with disruption of fronto-subcortical circuits, nigrostriatal dopaminergic, and cholinergic deficiency. Since no specific neuroimaging, neuropathological, or biomarker studies of depression in CBD are available, its pathobiological mechanisms and pathogenesis are poorly understood. Antidepressive therapy may be useful, but is often poorly tolerated. Depression in CBD, like in other parkinsonian syndromes, may be related to multi-regional patterns of cerebral disturbances and complex pathogenic mechanisms that deserve further elucidation as a basis for early diagnosis and adequate treatment to improve the quality of life in this fatal disease.
INTRODUCTION: Type 1 cryoglobulinemia is characterized by a large number of clinical signs. The lack of specificity of these signs can make diagnosis difficult. Ocular manifestations are rarely described across medical literature. Only 15 cases of ophthalmological involvement secondary to cryoglobulinaemia have been reported.
COMMENT: We report the case of a 69-year-old patient with cutaneous type 1 cryoglobulinaemia. He presented with bilateral anterior segment ischemia without retinal involvement with unilateral neovascularisation. Treatment of the B lymphocyte clone with rituximab and bendamustine and plasma exchange were initiated with successfully. Two similar cases describing ischaemic damage to the iris during type 1 cryoglobulinemia have been reported in the literature.
CONCLUSION: Irial ischaemia should be considered as a potential in type 1 cryoglobulinaemia.
Individuals with multiple sclerosis in the experimental group will be included in six sessions of EFT at seven-day intervals, in which one session lasts 30-45 minutes. SUDS will be applied before and after each EFT session. At the same time, resting heart rate and blood pressure will be measured in the EFT group before and after each session.
Participants with POMC)/PCSK1/LEPR biallelic mutations collectively referred to as PPL received setmelanotide at a dose of 0.5 milligrams (mg) per day (QD) via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.
In addition to participating in the multi-stressor training program, male participants randomized to the GnRH suppressed (SUPPRESS) group will be administered a long-acting GnRH agonist (Zoladex) by trained medical professionals to suppress endogenous gonadal steroids. Following GnRH agonist administration, men will be administered 1.25g/day (SUPPRESS) of topical 1% testosterone gel (AndroGel, Abbvie, North Chicago, IL) to be applied to the shoulders, upper arms, and/or stomach area daily.
The invention discloses an application of NSC668394 in preparing an iron death inhibitor and a medicament for preventing ischemia reperfusion injury. Iron death is closely related to kidney disease, organ ischemia reperfusion injury, cancer treatment, and the like. Heretofore, no document has directly demonstrated that NSC668394 is associated with iron death. Experimental results show that NSC668394 can remarkably inhibit iron death induced by a plurality of different iron death inducers, and is a novel iron death inhibitor with potential; in addition, animal experiments prove that NSC668394 can effectively relieve acute kidney injury induced by renal ischemia reperfusion of mice. The concentration of NSC668394 that inhibits iron death can be as low as 500nM. The renal ischemia reperfusion model demonstrates that NSC668394 is effective in ameliorating ischemia reperfusion injury of a renal organ at the tissue level.
<P>PROBLEM TO BE SOLVED: To provide a device for efficiently applying a coolant which is absorbed into a foam.  <P>SOLUTION: This device for dispensing the liquid coolant comprises: a vessel for retaining the liquid coolant; a valve which is connected to the vessel and closed in normal conditions; a dispensing element which has a carrier for holding an absorbing element via a plate, and which can be separated from other parts of the device; and a cap which is arranged on the upside of the vessel, and which has a chamber fitted for the arrangement of the absorbing element. The dispensing element can be attached to the cap by inserting the absorbing element into the chamber. A downside part of the chamber enables the opening of the valve by pushing in the dispensing element until the plate is brought into contact with an outside surface of the cap. The absorbing element absorbs the coolant immediately after discharge from the valve in the chamber.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to a liver cancer targeted adriamycin coupled segmented copolymer nano micelle, which utilizes a liver cancer specific antibody HAb18F (ab') 2 And (3) mediating the adriamycin coupling segmented copolymer nano micelle to carry out targeted therapy. The DOX-PLGA-PEG nano micelle is prepared by covalently coupling Doxorubicine (DOX) and lactic acid-glycolic acid copolymer (PLGA-PEG) through a chemical method to synthesize DOX-PLGA-PEG and utilizing a dialysis method. By HAb18F (ab') 2 The DOX-PLGA-PEG nano micelle is modified by physical adsorption of the antibody to prepare the targeting micelle. The targeted micelle is satisfactory in characterization, can be phagocytized and taken up by tumor cells, and the bioactive medicine is released from the micelle. The anti-liver cancer effect of the drug-loaded nano micelle is more obvious than that of a drug monomer, namely the targetThe micelle is accumulated in the local tumor in a large amount by virtue of the dual functions of passive targeting and active targeting, so that the curative effect is most remarkable. The invention obtains a novel drug delivery system which has high efficiency, low toxicity and targeted killing of liver cancer cells, improves the treatment effect of liver cancer, develops a novel antitumor nano-drug with definite curative effect and has wide application prospect.
The immune system and the kidneys are closely related. Immune components mediate acute kidney disease and are crucial to the progression of chronic kidney disease. Beyond its pathogenic functions, the immune system supports immunological homeostasis in healthy kidneys. The kidneys help maintain immune equilibrium by removing metabolic waste products and toxins, thereby limiting local and systemic inflammation. In this review, we describe the close relationship between the immune system and the kidneys. We discuss how the imbalance in the immune response can be deleterious to the kidneys and how immunomodulation can be important in preventing end-stage renal disease. In addition, recent tools such as in silico platforms and kidney organoids can help unveil the relationship between immune cells and kidney homeostasis.
Emtricitabine and Tenofovir Disoproxil Fumarate: HIV-1 isolates with reduced susceptibility to the combination of emtricitabine and tenofovir have been selected in cell culture. Genotypic analysis of these isolates identified the M184V/I and/or K65R amino acid substitutions in the viral RT.

In a clinical study of treatment-naive subjects [Study 934, see Clinical Studies (14.1)], resistance analysis was performed on HIV-1 isolates from all confirmed virologic failure subjects with >400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation. Development of efavirenz resistance-associated substitutions occurred most frequently and was similar between the treatment arms. The M184V amino acid substitution, associated with resistance to EMTRIVA and lamivudine, was observed in 2/19 analyzed subjects isolates in the EMTRIVA + VIREAD group and in 10/29 analyzed subjects isolates in the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects have developed a detectable K65R substitution in their HIV-1 as analyzed through standard genotypic analysis.
Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
The invention discloses an oral use decoction of a Chinese traditional medicine used for treating oligoleukocythemia, belonging to the field of Chinese traditional medicine. The oral use decoction of the Chinese traditional medicine for treating oligoleukocythemia is prepared by malaytea scurfpea fruit of 20g, suberect spatholobus of 20g, epimedium Herb of 15g, atractylodes ovata of 15g, indian bread of 12g, villous amomum fruit of 12g, cooked rehmannia root of 10g, the roots of Chinese angelica of 15g, red peony root of 20g, dried tangerine peel of 10g, glossy privet fruit of 15g and salvia root of 15g. First, the components are soaked in water for 2 hours and boiled for 30 minutes, and the liquid is poured out; then water is added to boil the components for 30 minutes, and the liquid is poured out; the liquid produced in the two times is mixed together, and water is distilled with small fire. The medicine is served after meal. One dose is divided into two shares served separately per day. 20 successive days is taken as one course.The invention has the effects of improving immunizing ability of organism and activating marrow sanguification function. The invention is characterized by wide material source, low price and easy obtaining as well as no toxic and adverse effects.
INTRODUCTION: Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is one of the strongest prodromal markers of alpha-synucleinopathies. We aimed to investigate non-invasive clinical and quantitative predictors of phenoconversion from iRBD to parkinsonism.
PATIENTS AND METHODS: We prospectively followed-up a total of 45 patients (57.8% men) for eight years. Clinical assessments, Sniffin' Sticks Odor Identification Test, Farnsworth-Munsell 100 Hue Color Vision test, Beck Depression Inventory and Rome III Criteria for constipation were performed. Polysomnographic parameters, sleep spindles, electroencephalographic (EEG) spectral analysis, heart rate variability (HRV) were analyzed.
RESULTS: Eight patients (17.8%) showed phenoconversion to parkinsonism after a mean duration of 3.2 ± 1 years. Odds ratio for predicting phenoconversion was highest for patients =60 years of age with anosmia and constipation -44.8 (4.5-445.7); kappa = 4.291-. Duration, frequency or density of sleep spindles failed to demonstrate significant correlations. In EEG spectral analysis, lower alpha power in occipital region during wakefulness and REM sleep was significantly correlated with phenoconversion. Slowing in EEG spectrum power, together with age =60 years, anosmia and constipation, resulted in the highest odds ratio -122.5 (9.7-1543.8); kappa = 3.051-.
CONCLUSIONS: It is of great importance to have a world-wide perspective of phenoconversion rates from iRBD to overt neurodegeneration, since racial and geographical factors may play important modifying roles. Relatively younger age and shorter disease duration may also be confounding factors for lower rate in our study. Neurophysiological biomarkers seem to be important predictors of phenoconversion, though more research is needed to establish subtypes of iRBD with different probabilities of evolution to overt synucleinopathy.
Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
Globally, obesity has become one of the major health problems. This study was conducted to evaluate the anti-obesity potential of Cymbopogon schoenanthus methanolic extract (CS) in rats. Fifty male Wistar rats of six to eight weeks old, 100-120 g body weight (BW) were randomly assigned into 5 groups (n = 10): The control group was fed a basal diet. CS-group was supplied with basal diet and orally given CS (200 mg/kg BW) for 12 weeks. HFD-group was fed a high-fat diet (HFD) for 18 weeks. HFD + CS-group was fed on HFD and CS HFD then CS-group was fed HFD for 12 weeks then shifted to basal diet and CS for another 6 weeks. Phytochemical analysis of CS indicated the presence of various terpenes and flavonoid compounds. Among the compounds characterized are quercetin, apigenin, luteolin, orientin, eudesmene, cymbopogonol, caffeic acid, coumaric acid, and linolenic acid. Supplementation of HFD significantly increased the body weight, levels of serum triacylglycerol, total cholesterol, very low-density lipoprotein, low-density lipo-protein (HDL), glucose, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities. In addition, HFD up-regulated the protein expression of uncoupling protein (UCP)-1 in both brown and white adipose tissue; and the expression of hepatic mRNA of sterol regulatory element-binding protein (SREBP)-1c and SREBP-2. However, it decreased the serum level of HDL, and protein expression level of UCP-1 in both brown and white adipose tissue. Treatment of HFD-fed animals with CS extract either concurrently (HFD + CS-group), or after obesity induction (HFD then CS-group) significantly reversed all HFD-induced alterations in body weight; food intake; serum biochemical profile (including hyperglycemia, dyslipidemia); and tissue gene expressions. These results indicate that CS methanolic extract ameliorated HFD-induced obesity, serum biochemical, hepatic, and adipose tissue gene expression alterations. CS extract accomplished these effects mostly through its various identified bioactive compounds which have been proven to have anti-obesity and anti-diabetic activities.